Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer
Open Access
- 3 April 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (12) , 2530-2538
Abstract
Purpose: Although radiotherapy (RT) is one of the primary treatment modalities used in the treatment of cancer, patients often experience toxicity during or after treatment. RT-induced genitourinary (GU) toxicity is a significant survivorship challenge for patients with prostate cancer, but identifying those at risk has been challenging. Herein, we attempt (i) to validate a previously identified biomarker of late RT-induced GU toxicity, PROSTOX, consisting primarily of miRNA-based germline biomarkers (mirSNPs), and (ii) investigate the possibility of temporally and genetically defining other forms of RT-associated GU toxicity. Experimental Design: We included 148 patients enrolled in Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE; NCT 04384770), a trial comparing MRI- versus CT-guided prostate stereotactic body RT. Linear regression was used to evaluate the association between PROSTOX score and late GU grade toxicity. Machine learning approaches were used to develop predictive models for acute toxicity and chronic GU toxicity, and the accuracy of all models was assessed using AUC metrics. A comparative Gene Ontology analysis was performed. Results: PROSTOX accurately predicts late GU toxicity, achieving an AUC of 0.76, and demonstrates strong correlation with GU toxicity grade (p-1.2E−9). mirSNP-based signatures can distinguish acute RT-associated GU toxicity and chronic RT-associated GU toxicity (AUCs of 0.770 and 0.763, respectively). Finally, Gene Ontology analysis identifies unique pathways involved in each form of GU toxicity: acute, chronic, and late. Conclusions: These findings provide strong evidence for the continued application of mirSNPs to predict toxicity to RT and act as a path for the continued personalization of RT with improved patient outcomes.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01CA238998, R01CA292795)
- National Cancer Institute (R01CA292795)
This publication has 44 references indexed in Scilit:
- KDM3B Single-Nucleotide Polymorphisms Impact Radiation Therapy Toxicity Through Circular RNA-Mediated KDM3B Expression and Inflammatory ResponsesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging–Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate CancerJAMA Oncology, 2023
- Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose ResponseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary ToxicityClinical Oncology, 2018
- The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell CancerJAMA Oncology, 2017
- Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate CancerEBioMedicine, 2016
- A Preliminary Study on Racial Differences in HMOX1, NFE2L2, and TGFβ1 Gene Polymorphisms and Radiation-Induced Late Normal Tissue ToxicityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Cytokine mediated tissue fibrosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Évaluation des effets secondaires des radiations ionisantesCancer/Radiothérapie, 2010